N@N

Bracco Reports Cardiac PET Growth

^{Published on 2010-06-18 07:20:39 - Market Wire}
 

INDIANAPOLIS--([ BUSINESS WIRE ])--Positron Corporation (OTCBB:POSC), a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology, cites an article posted on AuntMinnie.com, the largest community website for medical imaging professionals, relating to the growth in cardiac PET.

"The Bracco release further confirms our market growth prediction. We are seeing an unprecedented request for proposals and look forward to meeting the increasing demand."

Contrast agent developer[ Bracco Diagnostics ]said that the number of customers using its CardioGen-82 cardiac PET myocardial perfusion imaging (MPI) tracer has increased by 46% in comparison with June of 2009.

The Princeton, NJ-based vendor attributed the growth to increasing momentum for cardiac PET, publication of key clinical data, improvements in PET hardware/software technology and accessibility, and expanding society and academic advocacy for MPI.

Joseph Oliverio, Chief Technology Officer of Positron states, aThe Bracco release further confirms our market growth prediction. We are seeing an unprecedented request for proposals and look forward to meeting the increasing demand.a

About Positron: Positron founded in 1983, is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attriusa", a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assista", a radiopharmaceutical injection shield. Positron is headquartered in Indianapolis, Indiana. More information about Positron is available at [ www.positron.com ].

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Positron Corporation at (317) 576-0183.